Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 mass balance, absolute bioavailability, and pharmacokinetics study of 14C-ASTX029 in healthy volunteers
NL-OMON51576Phase 1Active, not recruiting
- Sponsor
- Astex Pharmaceuticals
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of beroterkib, sponsored by Astex Pharmaceuticals. Primary endpoints: Mass balance and excretion recovery and Absolute oral bioavailability. Started Jan 2023; status: active, not recruiting.
02
Drugs
beroterkib
Beyond the preview
Go deeper on NL-OMON51576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51576.